Asian Spectator

Men's Weekly

.

AweMed Series Sponsors Eczema Family Day 2025 to Support Singapore’s Sensitive Skin Community

SINGAPORE - Media OutReach Newswire - 3 July 2025 - AweMed®, a skincare brand developed in collaboration with local dermatologists and paediatricians, sponsored the Eczema Family Day 2025—a...

PrimeXBT Expands List of Trading Instruments, Reduces Minimum ...

VICTORIA, Seychelles, January 28, 2019, /PRNewswire-AsiaNet/-- PrimeXBT, a Bitcoin-based margin trading platform offering up to 1000x leverage across forex, stock indices, commodities, and c...

Hemanext Partners with Sickle Cell 101 to Sponsor Sickle Cell ...

LEXINGTON, Mass. and SAN FRANCISCO, July 29, 2021 /PRNewswire-AsiaNet/ -- -- Sickle Cell Disease (SCD) Affects Over 20M Worldwide, including 100K Americans[1],[2] Hemanext Inc. a privately h...

Discover the Gold Trading Guide from JustMarkets

JAKARTA, INDONESIA - Media OutReach Newswire - 19 February 2025 -Gold has always been one of the most popular assets for traders around the world, valued for its stability and market resili...

Dongfeng Motor Launches Flagship Innovation, Driving Global Value Chain Advancement with China Intelligent Manufacturing

HONG KONG SAR - Media OutReach Newswire - 13 June 2025 - The International Automotive & Supply Chain Expo (Hong Kong) 2025 opened on June 12, bringing together global industry leaders. ...

FIMER drives a new era for e-mobility

VIMERCATE, Italy, Nov. 11, 2020 /PRNewswire-AsiaNet/ -- - FIMER is entering the race for Electrical Vehicle (EV) chargers with the launch of a comprehensive new portfolio of residential and ...

/DISREGARD RELEASE: White Ops/

SINGAPORE, March 30, 2021 /PRNewswire-AsiaNet/ -- Journalists and other readers should disregard the news release "White Ops Reintroduces Itself as HUMAN, Signaling Cybersecurity Company's D...

Winner of Six Awards, Yili Further Elevated Its Profile as A W...

HOHHOT, China, June 16, 2022 /PRNewswire-AsiaNet/ -- From June 14-16, the 15th Global Dairy Congress was hosted in Laval, France. Dr. Zhanyou Yun, Assistant President of Yili Group, attended...

Nintex Announces 2020 Partner Award Program Finalists

AUCKLAND, New Zealand, June 25, 2020 /PRNewswire-AsiaNet/ -- -- Top partners highlighted for improving the way people work withthe Nintex Process PlatformNintex, the global standard for proc...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Terjebak budaya sungkan: Enggan komplain bisa menghambat perbaikan pelayanan publik

Sejumlah orang sedang menunggu antrean di ruangan di suatu fasilitas pelayanan publik di Jakarta. Zulkarnain.B/Shutterstock● Masih banyak masyarakat enggan komplain karena budaya sungkan dan tid...

Kamu nyaman curhat dengan AI? Hati-hati kena gangguan mental

Seorang perempuan sedang duduk sambil curhat dengan robot humanoid AI di sebuah ruang tamu.VesnaArt/Shutterstock● Kaum muda kini sering menjadikan ‘chatbot’ AI sebagai teman curhat.&...

Cemas saat berulang tahun? Simak tip psikolog untuk hadapi ‘birthday blues’

DavideAngelini/ShutterstockUlang tahun biasanya jadi momen membahagiakan penuh dengan tawa, perayaan, dan hadiah. Namun, tak jarang menjelang ulang tahun, kita justru merasa sedih.Ulang tahun dapat me...